Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by NC Ku
Abstract P6-20-02: Activity of Larotrectinib, a Highly Selective Inhibitor of Tropomyosin Receptor Kinase, in TRK Fusion Breast Cancers
Related publications
Abstract PR07: A Pediatric Phase 1 Study of Larotrectinib, a Highly Selective Inhibitor of the Tropomyosin Receptor Kinase (TRK) Family: An Updated Analysis
Methods for Identifying Patients With Tropomyosin Receptor Kinase (TRK) Fusion Cancer
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Larotrectinib OK'd for Cancers With TRK Fusions
Cancer Discovery
Oncology
Selective TRK Inhibitor CH7057288 Against TRK Fusion-Driven Cancer
Molecular Cancer Therapeutics
Cancer Research
Oncology
Identification of [18F]TRACK, a Fluorine-18-Labeled Tropomyosin Receptor Kinase (Trk) Inhibitor for PET Imaging
Larotrectinib Has Antitumor Activity in TRK + Pediatric Solid Tumors
Cancer Discovery
Oncology
CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase With Antitumor Activity in Experimental Models of Human Cancers
Molecular Cancer Therapeutics
Cancer Research
Oncology
Discovery of GNF-5837, a Selective TRK Inhibitor With Efficacy in Rodent Cancer Tumor Models
ACS Medicinal Chemistry Letters
Organic Chemistry
Biochemistry
Drug Discovery
Opioid Kappa Receptor Selective Agonist TRK-820 (Nalfurafine Hydrochloride)